West Pharmaceutical Q3 2026 Organic Sales Rise 11.9%

West Pharmaceutical Services reported stronger third-quarter 2026 sales and profitability as demand for high-value products supported growth in its Proprietary Products segment, outweighing a decline at West Vantage. Net sales increased 8.7% year over year to $874.5 million, while organic sales rose 11.9%.

Adjusted diluted earnings per share climbed 35.7% to $2.66 from $1.96 a year earlier. Adjusted operating margin expanded 420 basis points to 25.3%, and gross margin increased 310 basis points to 39.7%. On a U.S. GAAP basis, diluted EPS was $3.02, compared with $1.92 in the prior-year quarter; the latest result included the impact of M&A activity, including the sale of SmartDose 3.5mL.

High-value products drive segment growth

Proprietary Products sales rose 12.6% to $728.8 million and increased 16.6% organically, accounting for 83% of total company revenue. The segment’s operating margin expanded 450 basis points to 31.6%, while gross margin improved 360 basis points to 44.4%.

High-value product components generated $466.7 million in sales, up 19.7% as reported and 20.3% organically. West attributed the increase to volume, pricing and a favorable mix from conversions to higher-value components. Such conversions, including projects associated with Annex 1 requirements, contributed more than two percentage points of organic revenue growth. The company added 211 new upgrade projects during 2026 through the end of the third quarter.

High-value delivery-device sales were unchanged on a reported basis at $99.1 million but grew 26.4% organically after adjustments for currency and the SmartDose 3.5mL transaction. Administration Systems and Crystal Zenith each recorded strong double-digit growth, according to the presentation. Standard-product sales increased 2.9% to $163.0 million, or 3.1% organically.

Biologics remained West’s largest market group, representing 43% of quarterly sales. Revenue from the category rose 15.3% to $379.3 million and 23.2% organically. Pharma sales advanced 21.3% to $221.3 million, with organic growth of 21.4%, while generics revenue fell 5.7% to $128.2 million and declined 4.5% organically.

GLP-1-related business represented 21% of total sales, comprising 12% from elastomer products and 9% from West Vantage. Management identified GLP-1 therapies, biologics and regulatory-driven upgrades to high-value components as key growth opportunities.

West Vantage remains a drag

West Vantage sales declined 7.3% to $145.7 million, or 6.6% organically, because of the planned loss of a continuous glucose monitoring customer. The segment represented 17% of total company revenue.

West Vantage’s operating margin fell 360 basis points from a year earlier to 10.6%, although it improved 200 basis points sequentially. Gross margin decreased 280 basis points year over year to 16.5% but rose 230 basis points from the second quarter as the business recovered from a second-quarter cyber incident.

Geographically, Asia-Pacific delivered the strongest increase, with revenue rising 42.4% to $97.1 million and 41.9% organically. Americas sales increased 6.9% to $401.3 million, or 12.4% organically, while Europe, the Middle East and Africa revenue grew 4.2% to $376.1 million and 5.7% organically.

Guidance and capital allocation

West expects fourth-quarter revenue of $820 million to $830 million, representing organic growth of 6% to 7%. Adjusted EPS is projected at $2.22 to $2.32. The company estimates that foreign exchange will reduce fourth-quarter revenue growth by about 0.9 percentage points and adjusted EPS by approximately $0.04. The divestiture is expected to reduce fourth-quarter revenue growth by about 3.4 percentage points.

For full-year 2026, management forecasts revenue of $3.41 billion to $3.42 billion and organic growth of 11.3% to 11.6%. Adjusted EPS is expected to range from $9.38 to $9.48, compared with $7.29 in 2025. The company projects a tax rate of about 18% and capital spending of $215 million to $220 million.

West said its capital expenditures are focused on high-value product processing capacity for injectable therapies, network optimization and customers moving to higher-value components. The company also identified nearshoring as a potential opportunity.

For the first nine months of 2026, operating cash flow was $403.4 million, down from $503.7 million a year earlier. Capital expenditures declined to $125.0 million from $209.8 million, resulting in free cash flow of $278.4 million versus $293.9 million. West repurchased 2.4 million shares for $685.3 million during the period.

The outlook remains subject to currency movements, the effects of the SmartDose divestiture and operating pressures within West Vantage, including the planned customer loss. The company also noted that its forward-looking expectations are subject to broader risks and uncertainties described in its regulatory filings.